Castration|resistant prostate cancer monitoring by cell|free ...

Clinical implication of prognostic and predictive biomarkers for ...

However, most prostate cancer patients acquire resistance to the initial hormonal therapy and develop castration-resistant prostate cancer (CRPC) ...

'More Is Not Better' in Metastatic Castration-Resistant Prostate Cancer

Evaluate the role of emerging biomarkers and targets, especially PSMA, in improving detection and treatment of metastatic castration-resistant ...

Treatment After Progression in Metastatic Castration-Resistant ...

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining ...

First-line Treatment for Metastatic Castrate-resistant Prostate Cancer

Ryan CJ, Kheoh T, Li J, et al. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naive Metastatic Castration-Resistant ...

Olaparib in patients with metastatic castration-resistant prostate ...

Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to ...

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced ...

... castration-resistant prostate cancer (CRPC). Evidence ... Denosumab and bone-metastasis-free survival in men with castration-resistant ...

Prognosis of Castration-resistant Prostate Cancer Patients

Background: Detection of circulating tumor cells (CTC) in patients with castration-resistant prostate cancer (CRPC) may improve the estimate of chemotherapy ...

Screening of Drug Repositioning Candidates for Castration ...

Purpose: Most prostate cancers (PCs) initially respond to androgen deprivation therapy (ADT), but eventually many PC patients develop castration resistant PC ( ...

nmCRPC, a look in the continuous care of prostate cancer patients

Non-metastatic castration resistant prostate cancer (nmCRPC) is a clinical setting defined as confirmed rising levels of PSA in patients ...

Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate ...

... castration-resistant prostate cancer cell lines. Cancer Res. 2013, 73, 483–489. [Google Scholar] [CrossRef] [PubMed]; Cao, B.; Qi, Y.; Zhang ...

Prostate Cancer Workup - Medscape Reference

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo- ...

Understanding Metastatic Castration-Resistant Prostate Cancer

What is metastatic castration-resistant prostate cancer (MCRPC)? Daniel P. Petrylak, MD, professor of medicine and urology at the Yale ...

Consensus on management of castration-resistant prostate cancer ...

The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in ...

Prostate Cancer - Uroweb - European Association of Urology

... cancer on AS remained free of treatment five years after diagnosis [530]. ... Symptomatic management in metastatic castration-resistant prostate cancer.

Clinical and genomic insights into circulating tumor DNA-based ...

... prostate cancer and may be used to monitor minimal ... cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.

Prostate cancer - Diagnosis and treatment - Mayo Clinic

These tests look at the DNA of your actual cancer cells to compare them to other men, to come up with an individual risk profile for you and ...

Non-metastatic Castration-Resistant Prostate Cancer - OncLive

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

Nonmetastatic Castration-Resistant Prostate Cancer ... - FDA

Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials August 2021.

Metastatic Castration Resistant Prostate Cancer (mCRPC) - YouTube

castration-resistant prostate cancer (mCRPC). Dr. Petrylak ... What's New in Active Surveillance for Prostate Cancer. Memorial Sloan ...

177Lu-PSMA-I&T Shows PFS Benefit in mCRPC - Targeted Oncology

The pivotal phase 3 ECLIPSE trial met its primary end point in patients with metastatic castration-resistant prostate cancer (mCRPC) treated ...